Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

SAN FRANCISCO (Reuters) - Biogen (NASDAQ: BIIB) expects revenue from new launches to exceed its current sales by 2028 and ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

Looking at Biogen Inc.'s ( NASDAQ:BIIB ) insider transactions over the last year, we can see that insiders were ...

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...

European shares were lower today. The eurozone's STOXX 600 declined 0.45%, Germany's DAX 40 fell 0.26% and France's CAC 40 dipped 0.11%. Spain's IBEX 35 Index fell 0.23%, while London's FTSE 100 ...

Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...

Piper Sandler analyst David Amsellem reiterated a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $138.00. The ...